Pregnancy and Shots! Shots! Shots! An Update. Kelli D Barbour, MD 4 December 2015

Transcription

1 Pregnancy and Shots! Shots! Shots! An Update Kelli D Barbour, MD 4 December 2015

2 Objectives Review recommended adult vaccinations and pregnancy Review recommended immunizations in pregnancy and the puerperium Review international travel reference resources

3 VACCINATIONS

4 So many immunizations so little time Bacterial Diphtheria toxoid* Measles* Mumps* Tetanus toxoid* Pertussis* Pneumococcal-7, -13 Typhoid Plague vaccine Japanese encephalitis BCG Anthrax Meningococcal* A, C, Y, W-135 B

5 New vaccines

6 So many immunizations so little time Viral Adenovirus Hepatitis A* Hepatitis B* Haemophilus B* HPV-4, -9 Influenza A, B, A+B IM vs. intranasal Polio* Rotavirus Varicella Herpes Zoster Yellow fever Rabies Smallpox

7 Types of vaccinations Components Live, attenuated Inactivated Subunit Toxoid Conjugate DNA Recombinant vector IM SQ Intranasal PO Routes

8 I need a shot? But I m an adult!

9 Vaccines for the young at heart

10 Special considerations

11 RECOMMENDED IMMUNIZATIONS IN PREGNANCY AND THE PUERPERIUM

12 Resources

13 There is no evidence of adverse fetal effects from vaccinating pregnant women with an inactivated virus or bacterial vaccines or toxoids, and a growing body of robust data demonstrates safety of such use. Killed viruses preferred secondary to theoretical concern that inactivated viruses could become active

14 Published Jan 2015, Obstet Gynecol

15

16

17

18 Influenza - What RNA virus with A and B serotypes Both A and B cause endemic flu A causes pandemics A serotype demonstrates antigenic drift of two surface proteins Hemagglutinin Neuraminidase Each flu season 20% of the US population contracts the current virus; this increases to 50% during pandemics Among pregnant women, 20% develop upper respiratory-like illness; 10% have laboratory-confirmed influenza g.gif

19 Influenza + Pregnancy = Not good! Compared to the general population, pregnant women who contract influenza are at higher risk of: Hospital admission Cardiopulmonary complications Death Spontaneous abortion Perinatal mortality Preterm birth Low birth weight In the setting of a pandemic, these risks are even higher 2009 H1N1 5% of deaths occurred in pregnant women (only 1% of the population infected) Risk of preterm birth 3- fold higher

20 Influenza how and when No test for previous immunity Recommendation: Every pregnancy, during influenza season Gestational age not important IM ONLY! Benefits Maternal Decreased risk of illness between 36-70% Perinatal Reduction in low birth weight, preterm birth, fetal death Neonatal 29% reduction in respiratory illness 63% reduction in influenza at <6 months 90% reduced admissions for <6 months

21 Influenza immunization - Safety Vaccination No associated risk of adverse pregnancy outcomes for inactivated virus No evidence of risk in attenuated vaccine accidently given in the 1 st trimester

22 Tdap - What Bordetella pertussis bacteria whooping cough Highly contagious Pertussis is known to peak cyclically every 3 5 years, but the overall incidence has been steadily rising since the 1980s < 5000 cases in early 1980s 48,277 cases in ,231 cases in 2013 Unclear if the resurgence is due to mutations in the B pertussis bacteria Better awareness, identification, testing, reporting Waning of post-acellular vaccination immunity

23 Tdap Why? Pertussis-related morbidity and mortality disproportionately affects infants less than 12 months of age compared to other children or adults Infection occurs after exposure to a close contact (47-60% from parents) Most adults are asymptomatic or only have common cold symptoms Infants do not have enough immunity until at least 6 months of age (after 2-3 vaccination injections) pertussis2_iac.jpg

24 Tdap How and When? No testing for immunity - % immunity into adulthood New recommendation Cocooning strategy, focus on postpartum injection 2011 Vaccination antenatally March 2012 antenatal vaccination strongly endorsed by ACOG goal of stimulating maternal antibody production and transplacental passage to the fetus - providing passive immunity into the neonatal period Works best in the 3 rd trimester because of quick decrease in maternal antibody if given earlier Give in every pregnancy between weeks, at least 2 weeks before delivery

25 Tdap - Safety No adverse pregnancy outcomes noted, even with multiple inoculations over a few year time span many questions regarding vaccine effectiveness, optimal timing of vaccine administration, infant antibody correlates of protection, and safety of repeated close-interval dosing in multiparous women remain unanswered

26 Original Research Pregnancy Outcomes After Antepartum Tetanus, Diphtheria, and Acellular Pertussis Vaccination Jamie L. Morgan, MD, Sangameshwar R. Baggari, MBA, Donald D. McIntire, PhD, and Jeanne S. Sheffield, MD No adverse pregnancy outcomes were identified in association with antepartum Tdap vaccination OBJECTIVE: To evaluate pregnancy outcomes of women who received tetanus, diphtheria, and acellular pertussis (Tdap) vaccination at or after 32 weeks of gestation. Outcomes from consecutive pregnancies during which the mother received Tdap were also analyzed. RESULTS: Since 2013, 7,378 women who were offered the Tdap vaccine antenatally delivered at our institution: 7,152 accepted (97%). There was no difference in stillbirths, major malformations, chorioamnionitis, 5-minute CONCLUSION: No adverse pregnancy outcomes wer identified in association with antepartum Tdap vaccina tion. This remained true in women receiving more tha one Tdap vaccine in a 5-year timeframe. This may be th result of a type II error. This remained true in women receiving more METHODS: In a retrospective cohort study at a single (O bstet Gynecol 2015;125:1433 8) institution, we compared pregnancy outcomes between DO I: /AO G than one Tdap vaccine in a 5-year timeframe - those who accepted or declined Tdap at 32 weeks of LEVEL OF EVIDENCE: II gestation. Additionally, women who received Tdap vaccination in this and may a priorbe pregnancy the inresult the past 5of years a type Pertussis, II error were compared with multiparous women who only received Tdap in this pregnancy. a serious upper respiratory illness caused by the bacterium Bordetella pertussis, has histori cally been a major cause of morbidity and mortality particularly in infants and children. 1 Although pertus sis is known to peak cyclically every 3 5 years, th overall incidence has been steadily rising since th 1980s, with infants bearing a disproportionate illnes

27 MMR Rubella (German measles, 3-day measles) titer drawn as part of prenatal panel MMR given for those who are equivocal or non-immune Benefits Prevent possibility of infection in subsequent pregnancies, decreasing the risk of congenital rubella

28 Recommended based on presence of risk factors 23-valent pneumococcal polysaccharide vaccine Meningococcal Hepatitis A Hepatitis B

29 23-valent pneumococcal polysaccharide vaccine Immunocompromised Anatomical or functional asplenia Cerebrospinal fluid leaks or cochlear implants Smoke cigarettes Reside in nursing home or long-term care facilities Chronic heart disease (including congestive heart failure and cardiomyopathies, excluding hypertension) Chronic lung disease (including chronic obstructive lung disease, emphysema, and asthma) Chronic liver disease (including cirrhosis) Alcoholism Diabetes mellitus

30 Meningococcal Anatomical or functional asplenia Persistent complement component deficiencies Microbiologists routinely exposed to isolates of Neisseria meningitidis Repeat Q5 years Military recruits First-year college students up through age 21 years who are living in residence halls Persons at risk during an outbreak attributable to a vaccine serogroup Persons who travel to or live in countries in which meningococcal disease is hyperendemic or epidemic

31 Hepatitis A persons working with HAVinfected primates or with HAV in a research laboratory setting Chronic liver disease Persons who receive clotting factor concentrates Persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A Unvaccinated persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity

32 Hepatitis B Limited data indicate no apparent risk of adverse events to the mother or the developing fetus when hepatitis B vaccine is administered to pregnant women

33 Hepatitis B sexually active persons who are not in a long-term, mutually monogamous relationship persons seeking evaluation or treatment for a sexually transmitted disease (STD) Current or recent injection drug users End-stage renal disease HIV infection Chronic liver disease Diabetes Health care personnel and public safety workers who are potentially exposed to blood or other infectious body fluids Household contacts and sex partners of hepatitis B surface antigen positive persons, Clients and staff members of institutions for persons with developmental disabilities International travelers to countries with high or intermediate prevalence of chronic HBV infection

34 REVIEW INTERNATIONAL TRAVEL AND PROPHYLAXIS OF VARIOUS INFECTIONS

35 Best source of info for patients and clinicians

36 Hygiene! Hygiene! Hygiene! Hand-washing Safe drinking water Avoiding sick contacts

37 A few other traveling thoughts Malaria

38 Malaria prophylaxis/prevention Personal protection measures Bed nets Chemoprophylaxis Chloroquine Mefloquine (Lariam) Primaquine Doxycycline Atovaquone/Proguanil (Malarone)

39 Take Aways Utilize recommended vaccinations Give additional vaccinations as indicated Assess travel needs by country/countries Educate patients regarding hygiene, infection control

40 QUESTIONS